Biogen Idec's long-acting hemophilia A drug performed well in a late-stage study on children, the biotech said, giving it another Phase III victory as it races with rivals Bayer and Novo Nordisk to launch a more convenient treatment for the bleeding disorder.
New, long-acting hemophilia therapies are preparing to take the market by storm. For patients, they'll require less frequent infusions, proving more convenient. But for current market leaders like Baxter International, they could put millions in jeopardy as they take hold of the global markets for hemophilia A and B, worth a combined $7 billion.
Biogen Idec now has FDA approval for Alprolix, the first in a new wave of long-acting hemophilia treatments on their way to market. For Biogen, the thumbs-up is an opportunity to grab market share with a hemophilia B product that works three times as long as current clotting factors. But what will the ensuing market battle mean for Baxter?
Late on Friday the FDA announced that it had approved Biogen Idec's long-acting hemophilia B drug Alprolix, setting the stage for a rough-and-tumble showdown among the new and old generations of drugs competing for the blockbuster market.
George Scangos, CEO of biotech powerhouse Biogen Idec, and David Page, director of MIT's Whitehead Institute for Biomedical Research, have made a $5.3 million handshake, the Boston Globe reports, as the two institutions plan to collaborate on early-phase development.
With the departure of Astellas and now Biogen Idec, Aveo Oncology is fresh out of collaborators, sending the struggling biotech back to the partnering table as it looks to advance an early-stage cancer drug.
In the race to win FDA approval for a long-acting hemophilia A treatment, Novo Nordisk said its factor VIII therapy came through in a Phase III study, helping the Danish drugmaker play catchup in a three-way contest with Biogen Idec and Bayer.
How much is a pharma company's brand worth? More than $4 billion, if that pharma company is Pfizer. It's the most valuable pharma brand in the U.S., according to Brandirectory's latest iteration of the Billion Dollar Brands Club. For a company that's among the biggest prescription drug marketers in the world, that might not be so surprising.
The FDA said it needs three more months to consider Biogen Idec's Plegridy, an injectable multiple sclerosis treatment, delaying an expected midyear launch for the company's latest entrant in its blockbuster MS franchise.
Biogen Idec is partnering with Atlas Venture on a biotech launch, with the Big Biotech investing in the company, helping on R&D and taking an option to scoop up the entire package at the end of Phase I.